Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

1(25.0%)

N/A

1(25.0%)

Phase 3

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 2(1)

N/A(1)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07159789Not ApplicableRecruiting

Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis

Role: lead

NCT06765161Phase 3Recruiting

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Role: lead

NCT03047473Phase 2Completed

Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme

Role: lead

NCT02623946Completed

Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients

Role: lead

NCT02146534Phase 4Completed

Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients

Role: lead

NCT01658384Completed

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Role: lead

NCT03047460Completed

Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting

Role: lead

NCT02383550Completed

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension

Role: lead

All 8 trials loaded